HomeStartups IR-MED lifecycle

Claimed by owner Last Update Mar 18, 2026 Suggest Edits Claim Profile

Claimed by owner

IR-MED

Noninvasive Infrared-based Diagnostics

PUBLIC on OTCQB on Dec, 2020

IR-MED

IR-MED Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment

#Product Stage

IR-MED's Key Clinical and Media Milestones

#Product Stage #Investment

IR-MED Investor Update Letter - Sept-2025

#Product Stage #Investment

IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones

#Product Stage #Customers

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

#Product Stage #Investment

IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.

#Product Stage #Customers

Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries

#Customers #Partners

IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer

#Management Changes

IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company

#Customers #Expand

IRME: IR-Med’s Potential for Profitable Growth in Future Years Supports Price Target of $3.00.

#Investment

IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers

#Investment

IR-MED’s PressureSafe device cuts pressure injury incidence by half

#Investment #Customers

IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO

#Customers #Partners

IRME: IR-Med Announces 1st Quarter 2024 Financial and Operating Results

#Investment

IRME: IR-Med’s Potential for Profitable Growth in Coming Years Supports Price Target of $3.00.

#Investment

IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

#Customers #Partners #Expand

IRME: IR-Med’s positive safety and efficacy data from recent PressureSafe study supports price target of $3.00.

#Partners, Customers

IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries

#Customers #Partners #Expand

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

#Customers #Partners

IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine

#Customers #Expand

IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine

IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue

#Investment #Expand

IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue

IRME: IR-MED reports 3rd quarter financial results which were in line with expectations.

#Management Changes #Partners

IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer

#Management Changes

IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer

#Management Changes

IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024

#Partners #Expand

IR-MED Appoints Richard Serbin, Esq. to its Advisory Board

#Management Changes

IRME: Initiating coverage of IR-Med, Inc., a development stage medical device company that is creating a technology platform for non-invasive devices to be used as a decision support system tool (DSS).

#Customers

IR-MED Chairman & Interim CEO Issues Letter to Shareholders

#Public Trading #Customers #Expand

IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care

#Investment #Expand

IR-MED Honors Juneteenth with Commitment to Healthcare Equality: PressureSafe Device Sees Beneath the Skin to Address Inequality in Pressure Injuries

#Customers

IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device

#Partners #Investment

IR-Med’s PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium

#Customers

IR-Med to present at National Pressure Injury Advisory Panel 2023

IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY

IR-Med Gains Momentum in 2022

IR-Med Announces Dr. David Dalton as Advisory Board member

IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device

#Partners

IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries

#Investment

IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries

#Investment, Expand

IR-Med To Initiate Useability Study of its PressureSafe Device

#Partners #Expand

IR-Med To Initiate Useability Study of its PressureSafe Device

#Partners #Customers

IR-MED Names Moshe Gerber as New CEO

IR-Med Announces $3.2 Million Private Placement

IR-Med to Become Fully Reporting SEC Company

#Public Trading

IR-Med, Inc. Announces the Resignation of Limor Davidson Mund as CEO and Appointment of Chairman of the Board Oded Bashan as Interim Chief Executive Officer

#Management Changes

IR-Med, Inc. Announces FINRA Approval of Name Change and Ticker Symbol Change to "IRME"

#Public Trading

INTERNATIONAL DISPLAY ADVERTISING, INC. ANNOUNCES COMPLETION OF REVERSE MERGER AND CLOSING OF $2.2 MILLION PRIVATE PLACEMENT

#Acquisition #Investment

INTERNATIONAL DISPLAY ADVERTISING, INC AND IR MED LTD EXTEND OUTSIDE DATE OF SECURITIES EXCHANGE AGREEMENT

#Acquisition

International Display Advertising, Inc and ir Med Ltd Agree to Securities Exchange Agreement

#Acquisition #Investment

International Display Advertising, Inc. Announces Letter of Intent to Merge with IR Med Ltd.

#Acquisition #Management Changes

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

9/2012

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

IR-MED Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

News Over Time

News Articles

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment

#Product Stage

IR-MED's Key Clinical and Media Milestones

#Product Stage #Investment

IR-MED Investor Update Letter - Sept-2025

#Product Stage #Investment

IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones

#Product Stage #Customers

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

#Product Stage #Investment

IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.

#Product Stage #Customers

Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries

#Customers #Partners

IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer

#Management Changes

IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company

#Customers #Expand

IRME: IR-Med’s Potential for Profitable Growth in Future Years Supports Price Target of $3.00.

#Investment

IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers

#Investment

IR-MED’s PressureSafe device cuts pressure injury incidence by half

#Investment #Customers

IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO

#Customers #Partners

IRME: IR-Med Announces 1st Quarter 2024 Financial and Operating Results

#Investment

IRME: IR-Med’s Potential for Profitable Growth in Coming Years Supports Price Target of $3.00.

#Investment

IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

#Customers #Partners #Expand

IRME: IR-Med’s positive safety and efficacy data from recent PressureSafe study supports price target of $3.00.

#Partners, Customers

IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries

#Customers #Partners #Expand

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

#Customers #Partners

IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine

#Customers #Expand

IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine

IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue

#Investment #Expand

IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue

IRME: IR-MED reports 3rd quarter financial results which were in line with expectations.

#Management Changes #Partners

IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer

#Management Changes

IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer

#Management Changes

IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024

#Partners #Expand

IR-MED Appoints Richard Serbin, Esq. to its Advisory Board

#Management Changes

#Customers

IR-MED Chairman & Interim CEO Issues Letter to Shareholders

#Public Trading #Customers #Expand

#Investment #Expand

IR-MED Honors Juneteenth with Commitment to Healthcare Equality: PressureSafe Device Sees Beneath the Skin to Address Inequality in Pressure Injuries

#Customers

IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device

#Partners #Investment

IR-Med’s PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium

#Customers

IR-Med to present at National Pressure Injury Advisory Panel 2023

IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY

IR-Med Gains Momentum in 2022

IR-Med Announces Dr. David Dalton as Advisory Board member

IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device

#Partners

IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries

#Investment

IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries

#Investment, Expand

IR-Med To Initiate Useability Study of its PressureSafe Device

#Partners #Expand

IR-Med To Initiate Useability Study of its PressureSafe Device

#Partners #Customers

IR-MED Names Moshe Gerber as New CEO

IR-Med Announces $3.2 Million Private Placement

IR-Med to Become Fully Reporting SEC Company

#Public Trading

IR-Med, Inc. Announces the Resignation of Limor Davidson Mund as CEO and Appointment of Chairman of the Board Oded Bashan as Interim Chief Executive Officer

#Management Changes

IR-Med, Inc. Announces FINRA Approval of Name Change and Ticker Symbol Change to "IRME"

#Public Trading

INTERNATIONAL DISPLAY ADVERTISING, INC. ANNOUNCES COMPLETION OF REVERSE MERGER AND CLOSING OF $2.2 MILLION PRIVATE PLACEMENT

#Acquisition #Investment

INTERNATIONAL DISPLAY ADVERTISING, INC AND IR MED LTD EXTEND OUTSIDE DATE OF SECURITIES EXCHANGE AGREEMENT

#Acquisition

International Display Advertising, Inc and ir Med Ltd Agree to Securities Exchange Agreement

#Acquisition #Investment

International Display Advertising, Inc. Announces Letter of Intent to Merge with IR Med Ltd.

#Acquisition #Management Changes

IR-MED Internal

Create note

Notes

(undefined)

Filter notes

Content Writer

undefined

BI Verification

undefined

Phone Number

undefined

Israel Register ID

undefined

Confidence Score

undefined

Missing Fields

undefined

Profile Creator

undefined

Profile Update

undefined

Recent Updates

undefined

Create a free account to:

Startup Nation Finder

Your CSV is on the way

Upgrade your Finder plan

Provide your business email

Verify your business email

Create Watchlist

Add to List

Notifications settings

Email Alerts

No Notifications are selected

Suggest Edits

Thank You

Claim Profile

Password must contain:

Verify your email

Reset password

Check your mailbox

Password recovery

Tell us more about you

Save Search

Rename Search

Share saved search with others

Add to list

IR-MED Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

IR-MED Climate Tech relevance

Latest News

No Data, yet.

Similar Companies

Primary sector

Total funding

Funding stage

Number of employees

Founded

Team Members

Affiliated Organizations

Web & social links

Locations

Israel

Offices Abroad

Photos & videos

No Data, yet.

IR-MED Business

Business models

Product stage

Geographic markets

Products

Sector

Target Customer

Core Technology

Use Cases

Tech Community Involvement

Tags

IR-MED Financials

Cumulative Funding Raised Over Time ($)

No Data, yet.

Public Offerings & Exits

Private Equity Funding

Non-Equity Funding

Mergers and Acquisitions

IR-MED Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

No Data, yet.

IR-MED News

News Over Time

No Data, yet.

News Articles

Related Content

IR-MED Team

No Data, yet.

Employees Over Time

Similar Companies

IR-MED Internal

Create note

Notes

Add Article